Loading stock data…
PRFX
$1.43-0.04 (-2.42%)
Market OpenUpdated 3:36 PM EDT
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
PRF Technologies Ltd. in the Healthcare sector is trading at $1.43 with a market capitalization of $1M. The stock is currently near its 52-week low of $1.28, remaining 65.6% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$1.43
Potential Downside
0%
Whystock Fair Value$1.43
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
PRF Technologies Ltd., a specialty pharmaceutical company, focuses on reformulation of established therapeutics in Israel. It develops OcuRing-K, a bio-erodible sustained-release implant applied to the haptic of an intraocular lens for use in catarac...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.19M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.77
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-206.87%
Volume
Today's trading volume
336,637
Recent News
Top Premarket Gainers
PRF Technologies (PRFX) shares were up over 250% in Friday premarket activity after the company upda
EXCLUSIVE: PRF Technologies Advances Drop-Less Drug For Cataract Surgery Pain
The U.S. Food and Drug Administration (FDA) on Tuesday cleared PRF Technologies Ltd.'s Investigational New Drug application for OcuRing-K, enabling the company to move into a Phase 2 trial targeting pain and inflammation following cataract surgery. The milestone advances PRF's strategy to develop a sustained-release, drop-less therapy aimed at simplifying post-operative care. The company is focused on the reformulation of established therapeutics and developing AI-driven energy optimization tech
BC-Most Active Stocks
Gibo Holdings Ltd. 62,940,523 0.0274